NL950014I2 - Met sulfamoyl gesubstitueerde fenetylaminederivaten, de bereiding daarvan en farmaceutische preparaten, die deze derivaten bevatten. - Google Patents

Met sulfamoyl gesubstitueerde fenetylaminederivaten, de bereiding daarvan en farmaceutische preparaten, die deze derivaten bevatten.

Info

Publication number
NL950014I2
NL950014I2 NL950014C NL950014C NL950014I2 NL 950014 I2 NL950014 I2 NL 950014I2 NL 950014 C NL950014 C NL 950014C NL 950014 C NL950014 C NL 950014C NL 950014 I2 NL950014 I2 NL 950014I2
Authority
NL
Netherlands
Prior art keywords
derivatives
phenetylamine
sulfamoyl
substituted
preparation
Prior art date
Application number
NL950014C
Other languages
English (en)
Dutch (nl)
Other versions
NL950014I1 (nl
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11859488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL950014(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of NL950014I1 publication Critical patent/NL950014I1/nl
Publication of NL950014I2 publication Critical patent/NL950014I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/10—Radicals substituted by singly bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NL950014C 1980-02-08 1995-08-18 Met sulfamoyl gesubstitueerde fenetylaminederivaten, de bereiding daarvan en farmaceutische preparaten, die deze derivaten bevatten. NL950014I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1438280A JPS56110665A (en) 1980-02-08 1980-02-08 Sulfamoyl-substituted phenetylamine derivative and its preparation

Publications (2)

Publication Number Publication Date
NL950014I1 NL950014I1 (nl) 1996-12-02
NL950014I2 true NL950014I2 (nl) 1997-01-06

Family

ID=11859488

Family Applications (1)

Application Number Title Priority Date Filing Date
NL950014C NL950014I2 (nl) 1980-02-08 1995-08-18 Met sulfamoyl gesubstitueerde fenetylaminederivaten, de bereiding daarvan en farmaceutische preparaten, die deze derivaten bevatten.

Country Status (17)

Country Link
US (6) US4373106A (cg-RX-API-DMAC10.html)
EP (1) EP0034432B1 (cg-RX-API-DMAC10.html)
JP (1) JPS56110665A (cg-RX-API-DMAC10.html)
AR (2) AR227533A1 (cg-RX-API-DMAC10.html)
AT (1) ATE7223T1 (cg-RX-API-DMAC10.html)
AU (1) AU541720B2 (cg-RX-API-DMAC10.html)
CA (1) CA1177849A (cg-RX-API-DMAC10.html)
DE (2) DE3163257D1 (cg-RX-API-DMAC10.html)
ES (1) ES8201966A1 (cg-RX-API-DMAC10.html)
GR (1) GR73827B (cg-RX-API-DMAC10.html)
IE (1) IE50862B1 (cg-RX-API-DMAC10.html)
LU (1) LU90000I2 (cg-RX-API-DMAC10.html)
MX (2) MX6859E (cg-RX-API-DMAC10.html)
NL (1) NL950014I2 (cg-RX-API-DMAC10.html)
PT (1) PT72460B (cg-RX-API-DMAC10.html)
SU (3) SU1082320A3 (cg-RX-API-DMAC10.html)
UA (3) UA5990A1 (cg-RX-API-DMAC10.html)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
JPS62114952A (ja) * 1985-11-13 1987-05-26 Yamanouchi Pharmaceut Co Ltd 置換フエネチルアミン誘導体の製造法
JPH066565B2 (ja) * 1986-07-21 1994-01-26 山之内製薬株式会社 光学活性なベンゼンスルホンアミド誘導体の製造法
US4971990A (en) * 1988-02-19 1990-11-20 Hokuriku Pharmaceutical Co., Ltd. Phenoxyethylamine derivatives, for preparing the same and composition for exhibiting excellent α1 -blocking activity containing the same
ATE89719T1 (de) * 1989-09-04 1993-06-15 Yamanouchi Pharma Co Ltd Aeusserlich anzuwendende amusulosin enthaltende arzneizubereitung.
US5288759A (en) * 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
AU7085194A (en) * 1993-07-14 1995-02-13 Yamanouchi Pharmaceutical Co., Ltd. Remedy for urination disorder accompanying prostatic hypertrophy
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
FR2737494B1 (fr) 1995-08-04 1997-08-29 Synthelabo Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
EP0896516A1 (en) * 1996-04-12 1999-02-17 Beth Israel Deaconess Medical Center, Inc. Diabetic supplement bar
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
MXPA00010805A (es) * 1998-05-06 2002-05-08 Univ Duke Metodo para el tratamiento de sindromes de la vejiga y del tracto urinario inferior.
TW536402B (en) 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
KR100639543B1 (ko) 1998-09-30 2006-10-31 다케다 야쿠힌 고교 가부시키가이샤 방광 배출력 개선제
ID30249A (id) * 1999-08-09 2001-11-15 Yamanouchi Pharma Co Ltd Komposisi farmasi untuk terapi gejala-gejala penyakit pelaksanaan fungsi saluran air kencing bawah
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
US6835853B2 (en) 2001-10-31 2004-12-28 Synthon Bv Process for resolution of tamsulosin and compounds, compositions, and processes associated therewith
NL1021822C2 (nl) * 2001-11-07 2003-07-15 Synthon Bv Tamsulosinetabletten.
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
EA008377B1 (ru) 2002-04-24 2007-04-27 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Фармацевтическая комбинация для лечения доброкачественной гиперплазии простаты или для долговременной профилактики острой ишурии
US6894188B1 (en) * 2002-04-30 2005-05-17 Ranbaxy Laboratory Limited Tamsulosin derivative
ES2200699B1 (es) * 2002-07-12 2005-10-01 Ragactives, S.L Procedimiento para la separacion de r(-) y s(+)-5-(2-((2-(etoxifenoxi)etil)amino)propil-2-metoxibenceno-sulfonamida.
WO2004016582A1 (en) * 2002-08-14 2004-02-26 Natco Pharma Limited An improved process for the preparation of tamsulosin hydrochloride
KR100668539B1 (ko) 2002-08-19 2007-01-16 화이자 프로덕츠 인크. 과증식성 질환에 대한 조합요법
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US7018658B2 (en) 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
DE60232201D1 (de) * 2002-12-26 2009-06-10 Cadila Healthcare Ltd Verfahren zur zubereitung von enantiomerisch reinem (r) oder (s)-5-(2-aminopropyl)-2-methoxybenzensulfonamid
KR100503639B1 (ko) 2003-02-12 2005-07-26 보령제약 주식회사 탐술로신의 정제 방법
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
DE10315702A1 (de) * 2003-04-07 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Arzneitmittelkombinationen zur Behandlung von gutartiger Prostatahyperplasie oder zur Behandlung von abakterieller Prostatitis
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
CA2526730A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
CA2451175A1 (en) * 2003-11-26 2005-05-26 Torcan Chemical Ltd. Process for the preparation of tamsulosin
EP1692100A4 (en) * 2003-12-09 2007-11-21 Cj Corp PROCESS FOR THE PRODUCTION OF OPTICALLY PURE PHENETHYLAMINE DERIVATIVES
SI21656A (sl) * 2003-12-29 2005-06-30 LEK farmacevtska družba d.d. Priprava (R)-5-(2-(2-(2-etoksifenoksi) etilamino)-1-propil)-2-metoksibenzensulfonamida hidroklorida z visoko kemijsko čistoto
SI21655A (sl) * 2003-12-29 2005-06-30 LEK farmacevtska dru�ba d.d. Sinteza optično čistega (R)-5-(2-aminopropil)-2-metoksibenzensulfonamida
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
JP4800213B2 (ja) * 2004-07-07 2011-10-26 浜理薬品工業株式会社 光学活性フェニルプロピルアミン誘導体の製法
CN100545148C (zh) * 2004-08-16 2009-09-30 神隆新加坡私人有限公司 一种抗良性前列腺肥大药物坦索罗辛之合成方法
US7238839B2 (en) 2004-10-07 2007-07-03 Divi's Laboratories Limited Process for the resolution of racemic (R,S) -5-(2-(2-(2- ethoxyphenoxy) ethylamino)Propyl)-2-methoxybenzene sulfonamide (tamsulosin), its novel R and S isomers and their salts and processes for their preparation
PT103216B (pt) * 2004-12-06 2010-05-19 Hovione Farmaciencia S A Preparação de tamsulosin
EP1827404A2 (en) * 2004-12-13 2007-09-05 Boehringer Ingelheim Pharmaceuticals Inc. Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
ES2258394B1 (es) * 2004-12-31 2007-12-01 Quimica Sintetica, S.A. Procedimiento enzimatico para la preparacion de un compuesto intermedio y su uso en la sintesis de tamsulosina clorhidrato.
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
WO2006100557A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
CA2607809A1 (en) * 2005-05-04 2007-01-11 Medichem, S.A. Process for the preparation of tamsulosin
US20090137844A1 (en) * 2005-06-15 2009-05-28 Fermion Oy Crystallization process
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US8273918B2 (en) * 2005-09-12 2012-09-25 Avrobindo Pharma Ltd. Process for preparing tamsulosin hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
WO2007131804A1 (en) 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
AR063469A1 (es) * 2006-07-14 2009-01-28 Ranbaxy Lab Ltd Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades
WO2008021891A2 (en) * 2006-08-08 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
US20080113030A1 (en) * 2006-11-09 2008-05-15 Ching-Fen Hsiao Sustained release tamsulosin formulations
CN101190890B (zh) * 2006-11-30 2011-04-27 江苏豪森药业股份有限公司 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20080312328A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
EP2172201A4 (en) * 2007-07-20 2011-07-06 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION FOR THE REDUCTION OF LOWER HARNESS SYMPTOMS RELATED TO PROSTATE GAL
US20100261770A1 (en) 2007-12-21 2010-10-14 Astellas Pharma Inc. Pharmaceutical composition for improving lower urinary tract symptoms
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
SI2394648T1 (sl) 2009-02-04 2017-02-28 Astellas Pharma Inc. Farmacevtski sestavek za oralno dajanje
EP2255793A1 (en) 2009-05-28 2010-12-01 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising tamsulosin
ES3037313T3 (en) 2009-10-12 2025-09-30 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
CN102050766B (zh) * 2009-11-03 2013-08-07 安徽省新星药物开发有限责任公司 一种盐酸氨磺洛尔的合成方法
MX2012010077A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Vetmed Uso de meloxicam para el tratamiento a largo plazo de trastornos musculoesqueleticos en gatos.
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
BR102013020508B1 (pt) 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
EP2949319A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN106478467B (zh) * 2016-10-13 2018-07-13 深圳万和制药有限公司 制备稳定的盐酸坦索罗辛的方法
EP4035660A1 (en) 2017-10-17 2022-08-03 Synthon B.V. Tablets comprising tamsulosin and solifenacin
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
CN108037196B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法
MA54261B1 (fr) 2019-01-18 2025-03-28 Astrazeneca Ab Inhibiteurs de pcsk9 et leurs procédés d'utilisation
CN117049972B (zh) * 2023-08-25 2025-09-16 东莞理工学院 一种小分子酮肽的制备方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3701808A (en) * 1967-12-21 1972-10-31 Allen & Hanburys Ltd Phenylethanolamines
DE1957706C3 (de) * 1968-11-18 1978-06-29 Pfizer Corp., Colon (Panama) Kernsubstituierte 3-Phenoxy-l-phenoxyalkylamino-propan-2-ole und Arzneimittel auf deren Basis
US3878212A (en) * 1970-04-28 1975-04-15 Clemens Rufer Blood sugar lowering sulfamoyl pyrimidines and asymmetrical carbon atom
US4137328A (en) * 1970-07-18 1979-01-30 Pfizer Inc. Phenyl-alkanolamine, alkylamine and α-aminoalkyl ketone derivatives as heart stimulants
US3711545A (en) * 1971-02-23 1973-01-16 Smith Kline French Lab Alpha-aminoalkyl-4-hydroxy-3-sulfamoylaminobenzyl alcohols
DE2115926C3 (de) * 1971-04-01 1978-05-03 C.H. Boehringer Sohn, 6507 Ingelheim 1 -(4-Hydroxy-3-dimethylaminosuIfamidophenyI)-2-aminoäthanderivate, Verfahren zu ihrer Herstellung und diese enthaltende Mittel
US3860647A (en) * 1973-08-20 1975-01-14 Smithkline Corp {60 -Aminomethyl-4-hydroxy-3-sulfamyl-benzyl alcohols and 4-hydroxy-3-sulfamyl phenethylamines
GB1593651A (en) * 1977-02-03 1981-07-22 Allen & Hanburys Ltd Amides
CA1147342A (en) * 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US4558156A (en) * 1980-02-08 1985-12-10 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl-substituted phenethylamine derivatives
DE3110573A1 (de) * 1981-03-18 1982-10-21 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n- und o-substituierten di- und/oder polyurethanen
JPS5950671B2 (ja) * 1982-08-26 1984-12-10 山之内製薬株式会社 フェニルエタノ−ルアミン誘導体およびその製造法
US4558106A (en) * 1983-03-29 1985-12-10 Union Carbide Corporation Polymerization process using metal formate to reduce the color of thermoplastic copolymers

Also Published As

Publication number Publication date
DE3163257D1 (en) 1984-05-30
MX9203592A (es) 1992-07-31
AR230433A1 (es) 1984-04-30
ES499224A0 (es) 1982-01-01
US4987152A (en) 1991-01-22
AU6689681A (en) 1981-08-13
AU541720B2 (en) 1985-01-17
US4868216A (en) 1989-09-19
EP0034432A2 (en) 1981-08-26
US4703063A (en) 1987-10-27
CA1177849A (en) 1984-11-13
IE50862B1 (en) 1986-08-06
IE810236L (en) 1981-08-08
PT72460A (en) 1981-03-01
US4373106A (en) 1983-02-08
JPS6252742B2 (cg-RX-API-DMAC10.html) 1987-11-06
US4731478A (en) 1988-03-15
AR227533A1 (es) 1982-11-15
DE19675042I2 (de) 2001-06-13
UA5990A1 (uk) 1994-12-29
US4761500A (en) 1988-08-02
NL950014I1 (nl) 1996-12-02
JPS56110665A (en) 1981-09-01
SU1248533A3 (ru) 1986-07-30
GR73827B (cg-RX-API-DMAC10.html) 1984-05-04
ES8201966A1 (es) 1982-01-01
ATE7223T1 (de) 1984-05-15
EP0034432A3 (en) 1982-03-24
MX6859E (es) 1986-09-08
PT72460B (en) 1982-02-04
SU1181540A3 (ru) 1985-09-23
SU1082320A3 (ru) 1984-03-23
UA5980A1 (uk) 1994-12-29
LU90000I2 (fr) 1997-03-04
UA5981A1 (uk) 1994-12-29
EP0034432B1 (en) 1984-04-25

Similar Documents

Publication Publication Date Title
NL950014I2 (nl) Met sulfamoyl gesubstitueerde fenetylaminederivaten, de bereiding daarvan en farmaceutische preparaten, die deze derivaten bevatten.
NL190552C (nl) 1-Fenyl-4-alkyl-7,8-dialkoxy-5H-2,3-benzodiazepinederivaten en farmaceutische preparaten, die deze bevatten.
NL191738C (nl) ML-236B-derivaten, werkwijze voor hun bereiding en farmaceutische preparaten, die deze derivaten bevatten.
NL187401C (nl) Moleculaire cooerdinatiecomplexen, de bereiding daarvan, alsmede farmaceutische preparaten met beheerste afgifte die deze complexen bevatten.
NO801863L (no) Farmasoeytiske preparater.
NL7810520A (nl) Nieuwe 2,6-diaminonebularinen, alsmede farmaceutische preparaten die deze verbindingen bevatten.
DE3669104D1 (de) Pharmazeutische praeparate, die ascorbinsaeurederivate enthalten.
NL193819B (nl) Naftaleenderivaten alsmede farmaceutische en cosmetische preparaten, die deze derivaten bevatten.
NL191754C (nl) Farmaceutisch preparaat tegen acne.
NL8601838A (nl) Distamycinederivaten, werkwijze voor de bereiding ervan, alsmede farmaceutische preparaten, die deze derivaten bevatten.
NL7810865A (nl) 6,7-dialkoxy-4-piperidinochinazolinen, farmaceutische preparaten die ze bevatten, en werkwijzen voor de be- reiding daarvan.
NL190848C (nl) 2alfa-cyaan-4alfa,5alfa-epoxy-3-oxo-androstaanverbindingen, alsmede preparaten die deze verbindingen bevatten.
NL7803162A (nl) Nieuwe 1-aminoindaanderivaten, alsmede farmaceutische preparaten die deze bevatten.
NL184467C (nl) 6-oxo-prostaglandine eŸ1 derivaten, werkwijze voor de bereiding daarvan en farmaceutische preparaten, die deze bevatten.
NL194431B (nl) Farmaceutische preparaten die ranitidine bevatten.
NL188645C (nl) 1-azaxanthon-3-carbonzuurverbindingen en farmaceutische preparaten die deze verbindingen bevatten.
FI793375A7 (fi) Antikoagulantti, menetelmä sen valmistamiseksi ja sitä sisältävät farmaseuttiset valmisteet.
NL7900966A (nl) Nieuwe 3-fenyltetrahydropyridine-derivaten en de zouten daarvan, werkwijze ter bereiding daarvan, de toepassing daarvan als geneesmiddelen en farmaceutische prepara- ten, die deze derivaten bevatten.
NL7803448A (nl) Nieuwe benzothiadiazinederivaten, alsmede farmaceutische preparaten die deze verbindingen bevatten.
NL7902993A (nl) Nieuwe isochinolinederivaten, de bereiding ervan en farmaceutische preparaten, die de nieuwe isochinoline- derivaten bevatten.
NL7800383A (nl) Nieuwe isochinolinederivaten, de bereiding ervan en preparaten die de isochinolinederivaten bevatten.
NO811003L (no) Farmasoeytiske preparater.
FI803846A7 (fi) Farmaseuttiset valmisteet.
NL186860C (nl) N,n'-bis-(3-picolyl)-4-methoxy-isoftalamidemonohydraat, werkwijze voor de bereiding daarvan en farmaceutische preparaten, die dit bevatten.
NL7808440A (nl) Anti-inflammatoire 1-fenylethanolamine-derivaten, far- maceutische preparaten, die deze verbindingen bevatten en werkwijzen ter bereiding daarvan.